Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab After Radiation and Temozolomide in Patients With Newly Diagnosed With Glioblastoma Multiforme

NCT00904852 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Glioblastoma Multiforme

Interventions

DRUG: Tandutinib, bevacizumab, and temozolomide

Sponsor

Millennium Pharmaceuticals, Inc.